OCEANSIDE, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Therapeutics Solutions International, Inc.,
(OTC Markets:TSOI) announced today the formulation and initial clinical implementation of an injectable form of pterostilbene
called "IsoStilbene derived from their '047 patent."
As previously announced TSOI has licensed its entire StemVacs Platform that includes our peptide pulsed dendritic cell vaccine
(StemVacs), innaMune, MemoryMune, LymphoBoost, and NanoStilbene to Pan American Cancer Center ("Pan Am") in Tijuana Mexico.
"In adding IsoStilbene, an injectable formulation of pterostilbene, to Pan Am' arsenal of immuno-therapeutics, they now have the
ability to provide booster dosing of pterostilbene to supplement the 10ml daily intake of NanoStilbene patients already receive as
part of their overall treatment, by providing IsoStilbene intravenously," said Timothy Dixon, President and CEO of Therapeutic
Solutions International. "This is now the fourth commercial product derived from the issued '047 patent and we are very excited to
offer this to Pan Am as well," added Mr. Dixon.
Peer reviewed publications have demonstrated efficacy of the pterostilbene molecule at stimulating immunity to cancer, as well
as targeting cancer stem cells1,2. Unfortunately, classical formulations of pterostilbene do not appear to deliver effective
amounts of pterostilbene to cancer cells. For this reason, Therapeutic Solutions International has developed several alternative
dosing formulations including the previously disclosed NanoStilbene, and now, IsoStilbene.
"Pterostilbene is a highly potent analogue of resveratrol, which has been shown by multiple investigators to possess therapeutic
benefits in a variety of models of cancer. The current progress by the Company, combined with collaborators at the Pan Am Cancer
Treatment Center, allows for rapid translation of these non-toxic cancer immunotherapeutic approaches to the clinic," said James
Veltmeyer, MD, Chief Medical Officer of TSOI.
1 Huang et al. Modulation of macrophage polarization and lung cancer cell stemness by MUC1 and development of a related
small-molecule inhibitor pterostilbene. Oncotarget. 2016 Jun 28;7(26):39363-39375. http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=8101&pubmed-linkout=1
2 Mak et al. Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells
within tumor microenvironment and metastasis via modulating NF-B/microRNA 448 circuit. Mol Nutr Food Res. 2013
Jul;57(7):1123-34. https://www.ncbi.nlm.nih.gov/pubmed/23504987
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.
Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system.
The Company's corporate website is www.therapeuticsolutionsint.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these
words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press
release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy,
outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future
events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and
uncertainties that could cause actual results to differ materially from the statements made.
CONTACT INFORMATION
